What is AmideBio?
AmideBio operates at the intersection of computational biology and pharmaceutical manufacturing. The company specializes in the development of novel peptide drug candidates, utilizing advanced in-silico design methodologies to target metabolic diseases. Beyond its internal pipeline, AmideBio provides high-purity peptide synthesis services to a global clientele, including major pharmaceutical and biotechnology firms. This dual-revenue model—combining high-margin drug discovery with reliable contract research services—positions the company as a critical infrastructure provider in the therapeutic development ecosystem. Their focus on cost-effective, high-quality peptide production addresses a significant bottleneck in modern drug development, allowing for faster iteration cycles in the pursuit of metabolic disease treatments.
How much funding has AmideBio raised?
AmideBio has raised a total of $3.5M across 2 funding rounds:
Private Equity
$763K
Grant
$2.7M
Private Equity (2017): $763K, investors not publicly disclosed
Grant (2022): $2.7M led by The National Institute of Diabetes and Digestive and Kidney Diseases
Key Investors in AmideBio
The National Institute of Diabetes and Digestive and Kidney Diseases
A federal research agency under the NIH that provides critical grant funding to support high-impact medical research and therapeutic innovation.
Undisclosed Private Equity Investor
A private equity entity focused on long-term capital appreciation within the life sciences and biotechnology sectors.
Undisclosed Strategic Partner
An undisclosed participant providing strategic backing to support the commercialization of peptide-based therapeutic platforms.
What's next for AmideBio?
With the recent influx of capital, AmideBio is poised to accelerate its clinical development programs and expand its manufacturing capacity. The strategic focus will likely shift toward scaling its in-silico design capabilities to address a broader range of therapeutic targets. As the company matures, the integration of its proprietary synthesis technology into larger-scale commercial pipelines will be essential for maintaining its competitive edge. Investors and industry observers will be monitoring the firm's ability to translate its research-grade peptide candidates into viable clinical assets, a move that would significantly enhance its valuation and market influence in the metabolic disease space.
See full AmideBio company page
